After Robert W. Baird and H.C. Wainwright gave Leap Therapeutics (NASDAQ: LPTX) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics today and set a price target of $6.00. The company’s shares closed last Thursday at $2.52.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 14.8% and a 42.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Leap Therapeutics is a Strong Buy with an average price target of $4.83.
Based on Leap Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $375K and GAAP net loss of $11.14 million. In comparison, last year the company earned revenue of $375K and had a GAAP net loss of $7.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX: